Steven K Lundy
Overview
Explore the profile of Steven K Lundy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirabelli C, Jones M, Young V, Kolawole A, Owusu I, Shan M, et al.
mBio
. 2022 Apr;
13(2):e0017522.
PMID: 35404121
Human norovirus (HNoV) is a global health and socioeconomic burden, estimated to infect every individual at least five times during their lifetime. The underlying mechanism for the potential lack of...
2.
Fox D, Lundy S, Whitfield M, Berrocal V, Campbell P, Rasmussen S, et al.
Arthritis Res Ther
. 2021 Mar;
23(1):73.
PMID: 33663570
No abstract available.
3.
Nandedkar-Kulkarni N, Esakov E, Gregg B, Atkinson M, Rogers D, Horner J, et al.
J Immunol
. 2021 Mar;
206(7):1443-1453.
PMID: 33658296
Insulin receptor (IR) expression on the T cell surface can indicate an activated state; however, the IR is also chemotactic, enabling T cells with high IR expression to physically move...
4.
Lundy S, Taitano S, van der Vlugt L
Methods Mol Biol
. 2021 Jan;
2270:149-178.
PMID: 33479898
B lymphocytes make several contributions to immune regulation including production of antibodies with regulatory properties, release of immune suppressive cytokines, and expression of death-inducing ligands. A role for Fas ligand...
5.
Fox D, Lundy S, Whitfield M, Berrocal V, Campbell P, Rasmussen S, et al.
Arthritis Res Ther
. 2021 Jan;
23(1):10.
PMID: 33407866
Background: Abnormalities in lymphocyte surface markers and functions have been described in systemic sclerosis (SSc), but conflicting results abound, and these studies often examined patients with heterogeneous disease duration, severity,...
6.
Stanwyck L, Chan W, Sood A, Susarla G, Romano J, Pefkianaki M, et al.
Transl Vis Sci Technol
. 2020 Aug;
9(7):15.
PMID: 32832222
Purpose: To determine if immunological markers (1) are significantly different between autoimmune retinopathy (AIR) patients and controls and (2) correlate with disease progression in AIR patients. Methods: We enrolled patients...
7.
Wu Q, Mills E, Wang Q, Dowling C, Fisher C, Kirch B, et al.
JCI Insight
. 2020 Jan;
5(3).
PMID: 31935197
BACKGROUNDSiponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) modulator recently approved for active secondary progressive multiple sclerosis (SPMS). The immunomodulatory effects of siponimod in SPMS have...
8.
Nikoopour E, Lin C, Sheskey S, Heckenlively J, Lundy S
J Immunol
. 2019 Jan;
202(4):1057-1068.
PMID: 30635390
Autoimmune retinopathy (AIR) is a treatable condition that manifests in acute and progressive vision loss in patients. It has recently been determined that AIR is associated with an imbalance of...
9.
Vonberg A, Acevedo-Calado M, Cox A, Pietropaolo S, Gianani R, Lundy S, et al.
JCI Insight
. 2018 Dec;
3(23).
PMID: 30518692
We describe a protective effect on autoimmune diabetes and reduced destructive insulitis in NOD.scid recipients following splenocyte injections from diabetic NOD donors and sorted CD19+ cells compared with NOD.scid recipients...
10.
Lundy S, Nikoopour E, Karoukis A, Ohara R, Othman M, Tagett R, et al.
Front Med (Lausanne)
. 2018 Oct;
5:249.
PMID: 30271775
Autoimmune retinopathy (AIR) causes rapidly progressive vision loss that is treatable but often is confused with other forms of retinal degeneration including retinitis pigmentosa (RP). Measurement of anti-retinal antibodies (ARA)...